Klinikgruppe Dr. Guth GmbH & Co. KG
- Address
- lock Available on a paid plan
Analytical, Diagnostic and Therapeutic Techniques and Equipment – Therapeutics
At Klinikgruppe Dr. Guth GmbH & Co. KG, researchers are evaluating novel therapeutic technologies aimed at improving organ protection during high‑risk procedures.
- Evaluation of angiotensin II as a primary vasopressor
- Assessment of device‑guided hemodynamic management
- Development of diagnostic algorithms for early kidney injury detection
- Integration of advanced monitoring in cardiac surgery
These studies support the site’s commitment to advancing analytical and therapeutic techniques that can reduce complications such as acute kidney injury in cardiovascular settings.
Diseases – Cardiovascular Diseases
The clinic’s cardiovascular program concentrates on chronic kidney disease, hypertension, and related heart outcomes, seeking better treatment strategies.
- Investigation of combined therapy with baxdrostat and dapagliflozin
- Exploration of blood pressure control on renal progression
- Study of cardiovascular death and heart‑failure events in CKD patients
- Monitoring of eGFR decline and kidney failure risk
Through these trials, the site aims to improve long‑term health for patients with chronic kidney disease and high blood pressure, aligning with European standards for cardiovascular research.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 2 by active trials.
- 1AstraZeneca AB1active
lock +1 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Klinikgruppe Dr. Guth GmbH & Co. KG
lock Showing 1 of 2 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Randomized Controlled Trial of Angiotensin II Versus Noradrenaline for Prevention of Cardiac Surgery-Associated Acute Kidney Injury | Universitaet Muenster | Phase I | Recruiting | Mar 2025 | — |
IMP list
lock Showing 1 of 4 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| ANGIOTENSIN II | 1 | Unknown | 2025-03-31 | 2025-03-31 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.